Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cyclosporine
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Assistance Publique – Hôpitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
Details : Cyclosporin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Cyclosporine
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Assistance Publique – Hôpitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ILT101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Assistance Publique – Hôpitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
Details : ILT101 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 22, 2020
Lead Product(s) : ILT101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Assistance Publique – Hôpitaux de Paris
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
